184 related articles for article (PubMed ID: 34615680)
1. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
Osipenko L
BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
[TBL] [Abstract][Full Text] [Related]
2. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
[TBL] [Abstract][Full Text] [Related]
3. Assessment of quality of data submitted for NICE technology appraisals over two decades.
Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
[TBL] [Abstract][Full Text] [Related]
4. Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals.
Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA
BMJ Open; 2022 Jan; 12(1):e052186. PubMed ID: 34992108
[TBL] [Abstract][Full Text] [Related]
5. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
6. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
7. The impact of rarity in NICE's health technology appraisals.
Clarke S; Ellis M; Brownrigg J
Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
[TBL] [Abstract][Full Text] [Related]
8. Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020.
Polak TB; Cucchi DGJ; Darrow JJ; Versteegh MM
BMJ Open; 2022 Apr; 12(4):e058279. PubMed ID: 35396306
[TBL] [Abstract][Full Text] [Related]
9. A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM.
Daly MJ; Elvidge J; Chantler T; Dawoud D
Front Pharmacol; 2022; 13():887298. PubMed ID: 35645790
[No Abstract] [Full Text] [Related]
10. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
Pennington BM
Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
[TBL] [Abstract][Full Text] [Related]
11. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
12. The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.
Carroll C; Kaltenthaler E; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Value Health; 2017 Jun; 20(6):785-791. PubMed ID: 28577696
[TBL] [Abstract][Full Text] [Related]
13. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
14. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
[No Abstract] [Full Text] [Related]
15. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
17. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
Leahy TP; Ramagopalan S; Sammon C
BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
[TBL] [Abstract][Full Text] [Related]
18. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
19. Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.
Garattini L; Freemantle N
Pharmacoeconomics; 2020 Jan; 38(1):121-122. PubMed ID: 31848899
[No Abstract] [Full Text] [Related]
20. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
